Ligand Pharmaceuticals
LGND
205 hedge funds and large institutions have $1.28B invested in Ligand Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 66 increasing their positions, 67 reducing their positions, and 23 closing their positions.
2,556% more call options, than puts
Call options by funds: $22.6M | Put options by funds: $852K
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
43% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 23
4% more funds holding
Funds holding: 197 → 205 (+8)
0.37% less ownership
Funds ownership: 141.45% → 141.08% (-0.37%)
1% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 67
4% less capital invested
Capital invested by funds: $1.33B → $1.28B (-$53.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
+$9.59M |
| 2 |
Millennium Management
New York
|
+$8.18M |
| 3 |
Impax Asset Management Group
London,
United Kingdom
|
+$4.71M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$4.06M |
| 5 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
+$2.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$12.5M |
| 2 |
Janus Henderson Group
London,
|
-$12M |
| 3 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$8.93M |
| 4 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$5.19M |
| 5 |
BlackRock
New York
|
-$3.7M |
LGND Hedge Fund Activity: Q3 2022 in Review
205 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q3 2022, worth a combined $1.28B — down 4% from $1.33B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new LGND positions and 23 closed out — a net gain of 10 holders — while 66 added to existing stakes and 67 trimmed.
The largest buyer was Man Group, opening a new position worth an estimated $9.59M. The largest seller was State Street, cutting an estimated $12.5M.
- 205 institutional investors held Ligand Pharmaceuticals (LGND) as of Q3 2022, up from 197 in Q2 2022.
- Funds reported $1.28B of Ligand Pharmaceuticals stock for Q3 2022, down 4% quarter-over-quarter.
- 33 funds opened new Ligand Pharmaceuticals positions in Q3 2022 and 23 closed out, a net change of +10 holders.
- The largest Ligand Pharmaceuticals buyer in Q3 2022 was Man Group, an estimated $9.59M added.
- The largest Ligand Pharmaceuticals seller in Q3 2022 was State Street, an estimated $12.5M sold.
Based on aggregated 13F filings for Q3 2022.